Business Context and Reporting Period
This Form 8-K is a current report filed by Xenomics, Inc. (not Cardiff Oncology, Inc., as noted in the metadata request) on November 19, 2008. The filing reports on corporate governance changes effective on the date of the report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and associated compensatory arrangements.
Material Changes
The primary material change reported is the departure of three directors effective November 19, 2008:
- Dr. Gianluigi Longinotti-Buitoni
- Dr. David Sidransky
- Mr. Abba Poliakoff
Upon resignation, the Board granted new stock options to these individuals:
- Dr. Longinotti-Buitoni: 162,667 shares
- Dr. Sidransky: 284,334 shares
- Mr. Poliakoff: 25,000 shares
All options have an exercise price of $0.79 per share and expire in November 2012. All previously held unvested options were terminated. Additionally, the Company agreed to indemnify the departing directors for three years against claims arising from their service.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on financial performance, or specific risk factors beyond the standard indemnification agreement.
Investor Verification Checklist
- Verify the correct registrant name is Xenomics, Inc., not Cardiff Oncology, Inc.
- Confirm the total number of new shares subject to option grants (472,001 shares).
- Review the impact of terminating unvested options on the company's equity compensation expense.
- Assess the potential dilution from the new options granted at $0.79 per share.